Besponsa is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 2. DOSAGE AND ADMINISTRATION. Males of reproductive potential should use effective contraception during treatment with BESPONSA and for at least 5 months after the last dose Are breastfeeding or plan to breastfeed. Avoid breastfeeding during treatment with BESPONSA and for at least 2 months after the final dose. When considering the use of BESPONSA as a treatment for relapsed or refractory B cell ALL, baseline CD22 positivity of > 0% using a validated and sensitive assay is required prior to initiating treatment (see section 5.1).. Learn about the risks & benefits of BESPONSA™, an Rx treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.. Drug Information on Besponsa (inotuzumab ozogamicin) includes drug pictures, side effects, drug interactions, directions for use, symptoms of overdose, and what to avoid.. inotuzumab ozogamicin (BESPONSA®) is accepted for restricted use within NHSScotland. Indication under review: as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL)..